DSMB recommends continuing BriaCell Phase 3 breast cancer study
BriaCell Therapeutics said its independent Data Safety Monitoring Board (DSMB) recommended continuing its Phase 3 metastatic breast cancer study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.